Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Betalutin (177Lu-DOTA-HH1) in relapsed CD37-positive follicular lymphoma
2015-001570-17Phase 2Terminated
- Sponsor
- Nordic Nanovector ASA
- Start
- Jul 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium (177Lu) lilotomab satetraxetan in follicular lymphoma (FL) (2 arms), sponsored by Nordic Nanovector ASA. Primary endpoint: Overall response rate at 3 months. Started Jul 2015; status: terminated.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2015-001570-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001570-17.